The effect of angiotensin receptor blockers for preventing atrial fibrillation
- PMID: 17686377
- DOI: 10.1007/s11906-007-0051-1
The effect of angiotensin receptor blockers for preventing atrial fibrillation
Abstract
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, and causes significant burden to patients and health care systems. Clinicians treat existing atrial fibrillation with anticoagulation and/or drugs that utilize either a rate or rhythm control strategy. It remains unclear how best to reduce cardiovascular morbidity and mortality in this population. Prevention of atrial fibrillation using angiotensin receptor blockers, which affect ion currents and refractoriness in atrial myocytes, regress or prevent atrial fibrosis, decrease left atrial size, regress left ventricular hypertrophy, modulate sympathetic nerve activity, reduce inflammation, and reduce blood pressure, may become an important and desirable alternative.
Similar articles
-
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.Curr Cardiol Rep. 2006 Sep;8(5):356-64. doi: 10.1007/s11886-006-0075-1. Curr Cardiol Rep. 2006. PMID: 16956451 Review.
-
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.J Hypertens. 2007 Jan;25(1):15-23. doi: 10.1097/01.hjh.0000254378.26607.1f. J Hypertens. 2007. PMID: 17143167 Review.
-
Angiotensin II receptor blockers in the prevention of atrial fibrillation.Expert Opin Pharmacother. 2009 Jun;10(9):1395-411. doi: 10.1517/14656560902973736. Expert Opin Pharmacother. 2009. PMID: 19466911 Review.
-
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Pharmacotherapy. 2009. PMID: 19113795 Review.
-
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38. doi: 10.2459/01.JCM.0000199778.85343.08. J Cardiovasc Med (Hagerstown). 2006. PMID: 16645357 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical